Brendan D Curti
Overview
Explore the profile of Brendan D Curti including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
52
Citations
2708
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
2.
Collins C, Khuat L, Sckisel G, Vick L, Minnar C, Dunai C, et al.
Front Immunol
. 2024 Sep;
15():1429912.
PMID: 39315105
The thymus is the central organ involved with T-cell development and the production of naïve T cells. During normal aging, the thymus undergoes marked involution, reducing naïve T-cell output and...
3.
Algazi A, Moon J, Lao C, Chmielowski B, Kendra K, Lewis K, et al.
Cancer
. 2024 Jan;
130(10):1784-1796.
PMID: 38261444
Background: Aberrant PI3K/AKT signaling in BRAF-mutant cancers contributes to resistance to BRAF inhibitors. The authors examined dual MAPK and PI3K pathway inhibition in patients who had BRAF-mutated solid tumors (ClinicalTrials.gov...
4.
Diab A, Gogas H, Sandhu S, Long G, Ascierto P, Larkin J, et al.
J Clin Oncol
. 2023 Aug;
41(30):4756-4767.
PMID: 37651676
Purpose: Despite marked advances in the treatment of unresectable or metastatic melanoma, the need for novel therapies remains. Bempegaldesleukin (BEMPEG), a pegylated interleukin-2 (IL-2) cytokine prodrug, demonstrated efficacy in the...
5.
Coveler A, Smith D, Phillips T, Curti B, Goel S, Mehta A, et al.
J Immunother Cancer
. 2023 Jun;
11(6).
PMID: 37385724
Background: SEA-CD40 is an investigational, non-fucosylated, humanized monoclonal IgG antibody that activates CD40, an immune-activating tumor necrosis factor receptor superfamily member. SEA-CD40 exhibits enhanced binding to activating FcγRIIIa, possibly enabling...
6.
Fox B, Urba W, Jensen S, Page D, Curti B, Sanborn R, et al.
Clin Cancer Res
. 2023 Apr;
29(12):2173-2175.
PMID: 37040070
The authors of a recent study identified noncanonical peptides (NCP) presented by cancer cells' HLA and observed lack of reactivity to these antigens by endogenous tumor-reactive T cells. In vitro...
7.
Kottschade L, Pond G, Olszanski A, Zakharia Y, Domingo-Musibay E, Hauke R, et al.
Clin Cancer Res
. 2023 Mar;
29(12):2220-2225.
PMID: 37000165
Purpose: Mucosal melanoma is a rare, aggressive form of melanoma with extremely high recurrence rates despite definitive surgical resection with curative intent. Currently there is no consensus on adjuvant therapy....
8.
Rudin C, Pandha H, Zibelman M, Akerley W, Harrington K, Day D, et al.
J Immunother Cancer
. 2023 Jan;
11(1).
PMID: 36669791
Background: Oncolytic virus V937 showed activity and safety with intratumoral administration. This phase 1 study evaluated intravenous V937±pembrolizumab in patients with advanced solid tumors. Methods: Patients had advanced non-small cell...
9.
Curti B, Richards J, Hyngstrom J, Daniels G, Faries M, Feun L, et al.
J Immunother Cancer
. 2022 Dec;
10(12).
PMID: 36564126
Background: Intratumoral administration of V937, a bioselected, genetically unmodified coxsackievirus A21, has previously demonstrated antitumor activity in patients with advanced melanoma as monotherapy and in combination with the programmed cell...
10.
Atkins M, Lee S, Chmielowski B, Tarhini A, Cohen G, Truong T, et al.
J Clin Oncol
. 2022 Sep;
41(2):186-197.
PMID: 36166727
Purpose: Combination programmed cell death protein 1/cytotoxic T-cell lymphocyte-4-blockade and dual BRAF/MEK inhibition have each shown significant clinical benefit in patients with -mutant metastatic melanoma, leading to broad regulatory approval....